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Reperfusão Farmacológica no Enfarte
Agudo do Miocárdio Depois do
ASSENT 3 e GUSTO V
The restoration of coronary flow after anacute myocardial infarction (AMI) has been
the most remarkable advance in the treatment
of acute coronary syndromes in recent
decades.
Pharmacological and mechanical ways of
achieving rapid and complete reperfusion of
epicardial arteries have been the goal of many
clinical trials.
Questions such as whether PCI is superior
to fibrinolysis, or if bolus lytics are superior to
perfusion drugs, or which is the best regimen
of adjunctive therapy to fibrinolysis, have been
extensively addressed.
Thrombolytic agents have become the
cornerstone of pharmacologic treatment for
acute myocardial infarction. However, the
current agents are far from perfect. New
thrombolytic drugs have been designed to
overcome some of the shortcomings of the old
drugs.
Development of these agents has focused
not only on increasing plasma half-life, and
thus allowing single-bolus administration, but
also on improving fibrin specificity and
resistance to plasminogen activator inhibitor.
The safety and efficacy of several of these
promising thrombolytic drugs have been
evaluated in large-scale trials.
The two most recent large scale clinical
trials on fibrinolysis for AMI (ASSENT 3 and
GUSTO V) (1, 2) have addressed some of the burn-
ing questions:
– Are bolus lytics equivalent (in terms of
efficacy and safety) to perfusion lytics?
– Can enoxaparin replace unfractionated
heparin (UFH) as adjunctive
antithrombotic therapy for fibrinolysis?
– Does the regimen with association of a
lytic drug with abxicimab (an IIbIIIa
glycoprotein inhibitor) confer equal
efficacy with better safety?
Trial designs and endpoints
The primary hypothesis of GUSTO V was
that a IIb/IIIa antagonist with reduced-dose
fibrinolytic therapy for emergency treatment of
STEMI would improve clinical outcomes with
equal or superior safety as compared with
conventional thrombolysis. The primary end
point was all-cause mortality at 30 days, and
secondary end points included clinical safety
and adverse events at 30 days. GUSTO V
enrolled 16,588 patients who were in the first
6 hours of an evolving STEMI. Patients were
randomly assigned to a standard-dose r-PA arm
(n=8,260), or a halfdose r-PA with full-dose
abciximab arm (n=8,328) (2).
The ASSENT-3 trial (1) was designed to
evaluate LMWH, abciximab and TNK in the
treatment of STEMI. Six thousand patients
were involved in the blinded, three-arm study
that compared TNK plus unfractionated
heparin (UFH) (n=2,038), half-dose TNK plus
abciximab and UFH (n=2,017), and TNK plus
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LMWH (enoxaparin) (n=2,040). The composite
efficacy end points of ASSENT-3 were reported
in two sets: efficacy, and safety/efficacy. The
arms that include enoxaparin and abciximab
versus UFH are reported together and cannot
be evaluated individually, but trend together.
Trial Main Results
In the GUSTO V trial (2), at 30 days, 5.9%
of the patients in the r-PA group had died
compared with 5.6% of patients in the combin-
ed r-PA/abciximab group (p=0.43; 95% CI=
0.83-1.08). The combined outcome of deaths
or nonfatal reinfarction was less common in
the combination group than with r-PA alone,
and there was less need for urgent
revascularization and fewer nonfatal ischemic
complications of AMI. Although rates of ICH
(0.6%) and nonfatal disabling stroke (0.9%)
were similar between the two groups, there
were more non-intracranial bleeding
complications in the combination therapy
group. 
While the combination of r-PA/abciximab
showed the same 30-day mortality as r-PA
alone, there were significant improvements in
several secondary end points. From an efficacy
perspective, there was a lower need for PCI with-
in the first week in the combination group
(25.4 %) compared with r-PA alone (27.9 %)
(p=0.008). Rates for coronary artery bypass
graft were 3 % for r-PA alone versus 3.7 % for
combination therapy (p=0.013). Furthermore,
the combined end point of death and nonfatal
reinfarction was lower with combination ther-
apy (7.4%) than with r-PA alone (8.8 %)
(p=0.0011) (2).
With regard to ICH, there was no difference
between the groups (p=0.27) if the patients
were younger than 75 years old. However,
when a patient was older than 75, there was a
significant interaction for ICH (p=0.033) (2).
Combination therapy is not recommended in
this cohort, therefore this is a post-hoc non-
prespecified analysis.
Similar to GUSTO V, the ASSENT III group
which was treated with a combination of half-
dose TNK and abciximab demonstrated a
reduction in the efficacy endpoint compared to
standard-dose TNK and heparin (11.1 %
versus 15.4 %, p=0.0001) (1). Reinfarction was
significantly reduced with the combination arm
(2.2 % versus 4.2 %, p=0.0009), and refractory
ischemia was significantly reduced as well
(3.2 % versus 6.5 %, p=0.0001).
Non-intracranial bleeding, however, was
increased in the combination arm (4.3 %1006
versus 2.2 %, p=0.0005). Intracranial bleeding
was similar between the combination arm
(0.9 %) and the control group (p=0.98). These
results mirror the results of GUSTO V, adding
credibility to the argument that the addition of
a IIb/IIIa agent to half-dose fibrinolytics has
advantages beyond mortality reduction alone.
Reinfarction and refractory ischemia are
significantly reduced with the addition of a
IIb/IIIa agent.
Some lessons can be taken from these two
(and from previous) trials and are addressed in
this article.
Lesson #1
Bolus fibrinolytics overtake
accelerated tPA as standard drug
for lytic therapy
Previous studies had demonstrated that
“bolus lytics” were “non inferior” as compared
with accelerated-tPA but they have indeed fail-
ed to demonstrate superiority (3, 4).
This notion was already incorporated into
both the ASSENT 3 and GUSTO V trials,
where bolus drugs were used, suggesting that
these more fibrin specific drugs have came to
stay in terms of fibrinolytic therapy for AMI.
If the bolus drugs are not better, not safer
and not cheaper, then the main reason for
changing from the conventional gold-standard
drugs (like SK or alteplase) to the new drugs
(reteplase or tenectepla-se) must be because
they are easier to use, allowing for significant
reductions in nursing time and the need for
perfusion systems.
Lesson #2
Bolus lytics allow for significant
reductions in dosing errors
Some third-generation fibrinolytics may
help reduce medical errors in administering
medications.
Simplicity of the administration regimen
and weight adjustment are just two of the
aspects related to the more frequent errors.
Data from several large-scale trials indicate
that, the more complicated the fibrinolytic
regimen, the higher the likelihood of
medication error, which is associated with
increased mortality (5).
The other aspect of safe lytic administration
is weight-based dosing. In the ASSENT-2 trial,
only 53 % of patients were weighed (4). When
the patients in ASSENT-2 who were not weigh-
ed are analyzed, mortality triples. FDA post-
hoc analysis of the ASSENT-1 and ASSENT-2
trials showed that patients with estimated
weights who received weight-adjusted drugs
had higher morbidity and mortality than pa-
tients with accurate weights. The outcome
differences may be the result of the inability to
obtain a weight in the critically ill patient,
rather than a treatment effect.
A dosing error is probably even more
important in smaller patients, where dose-
weight discrepancies have a greater impact in
terms of percentage. The National Registry of
Medical Infarction (NRMI) registry showed
that patients receiving >1.5 mg/kg t-PA have
1.2 to 2 times the risk of ICH (5).
A bolus administration regimen can reduce
errors and increase the safety and effectiveness
of treatment. This is important, since the ther-
apeutic window for fibrinolytic therapy is small
and the potential for adverse outcomes from
errors is high. This is particularly a concern in
EDs whose staff does not routinely treat a large
volume of patients with high-risk AMI. Bolus-
dose therapy that does not require a patient’s
weight to be obtained is more convenient and
may also be safer.
Lesson #3
GUSTO V and ASSENT 3 did
not shorten time to treatment
Despite the fact that bolus drugs were used
in both trials, the median time between first
symptoms and first study drug was not
significantly different from previous lytic
studies.  The median time to treatment was
2.7h in both ASSENT 3 and GUSTO V,
compared with 2.8h in GUSTO I that was
performed between 1990 and 1993 (6).
We can conclude that bolus treatment may
be easier to use but this did not result in
shorter time to treatment. The time spent by
the patient to get help, together with the time
spent by doctors to make the decision to start
treatment, did not change significantly over the
last decade.
Significant reductions in time to treatment
could only be achieved by taking the
reperfusion treatment to the pre-hospital
environment, as shown in the recent ASSENT
3 PLUS trial, where the median time to
treatment was reduced to 115 min (7). The ease
of use of bolus drugs makes them the
preferable choice for out-of-hospital lytic
treatment.
1007
Lesson #4
Lowest 30-day mortality ever achieved in
lytic trials
For the first time in in-hospital lytic trials,
the 30-day mortality was reduced to less than
6 % in both trials and in several arms.
Mortality at 30 days was reduced from
7.4 % to 5.9 % in patients receiving reteplase
and UHF from GUSTO III to GUSTO V (3, 2).
Similar results were shown from ASSENT 2 to
ASSENT 3 in patients receiving TNK-tPA and
UHF with 30-day mortality being reduced from
6.17 % to 6.0 %, respectively (4, 1).
One of the possible explanations for these
results is that the more recent trials had
relatively low risk populations. Indeed, there
was a lower rate of anterior MIs, patients with
a single elevated blood pressure were excluded
in GUSTO V and there were fewer patients
with previous MI in ASSENT 3, than in
previous trials.
Lesson #5
Early patency did not translate into
lower mortality
Pilot studies with the combination of half-
dose lytics and abxicimab (like SPEED and
TIMI 14 trials) (8, 9) raised the hypothesis that
better patency could result in significantly low-
er mortality rates in clinical practice.
The large RCTs analyzed here, however, did
not show lower mortality of the combination as
compared with conventional lytic therapy.
These results come as no surprise if a
closer and deeper interpretation of the results
of previous trials is made.
Back in the GUSTO I trial, a 20 % im-
provement in TIMI 3 flow was needed to yield
a 1 % mortality reduction (10).
In the dose-confirmation phase (core
laboratory assessment) of the SPEED trial
(considered as a pilot trial for the GUSTO V),
there was a 7 % improvement in the rate of
TIMI grade 3 flow (8). Therefore, if a 20 %
improvement is required to improve mortality
by 1 %, then a 7 % improvement would be
predicted to improve mortality by 0.3 %. And
that was exactly what was found in the GUSTO
V (a 0.29 % absolute reduction in 30-day
mortality for the combination therapy) (2).
These results led to the idea that trying to
further improve reperfusion with drugs is
probably not worthwhile. Future management
of MI could consist of treatment with a
fibrinolytic or with combination therapy,
followed by immediate angioplasty.
However, to the question “could the
combination therapy facilitate early PCI?” we
have to reply: “Answer not yet given!”.
Although no excess bleeding was reported
among patients undergoing PCI, in these two
trials, the power of this analysis is limited 
given the small sample sizes.
Patients were not randomized to PCI vs no
PCI and substudy analyses such as this are
potentially biased.
Future large scale randomized trials are 
needed to address the efficacy of the facilitated
PCI strategy.
GUSTO V and ASSENT 3 did not provide
supportive data for this strategy.
Lesson #6
Abxicimab use allowed half-dose lytic
therapy with noninferior efficacy and
with no increase of hemorragic risk
No differences were found in primary
endpoints, in both studies, between
combination and conventional lytic therapy.
The feared increase of severe hemorraghic
complications (namely of intracranial
haemorrhage) with the combination therapy
was not confirmed.
Lesson #7
Some subgroups seemed to benefit more
from the combination therapy
Despite its risks and limitations, subgroup
analysis showed some subgroups in which the
combination of abxicimab and lytics appeared
more beneficial.
* Patients aged less than 75 years in both
trials
* Patients with anterior MI in GUSTO V
* Patients treated after 4h in GUSTO V and
less than 4h in ASSENT 3
Lesson #8
Some subgroups did worse with the
combination therapy
On the other hand, subgroup analysis also
showed some subgroups in which this
combination appeared more detrimental.
* Patients older than 75 years in both trials
* Diabetics in ASSENT 3
This analysis led to the next conclusion:
1008
Lesson #9
The combination arm was harmful to the
elderly in both GUSTO V and ASSENT 3
At this stage, we should recommend against
combined abxicimab and fibrinolytic in the
elderly.
Caution should also be exercised when
dealing with diabetics.
Should we be studying direct PCI or some
facilitated approach for the elderly?
Lesson #10
Benefit was due to lower incidence
of ischemic events
Although mortality did not show significant
differences between treatments arms, both the
combination of abxicimab + lytics and
enoxaparin + lytics showed fewer ischemic
events during in-hospital stay.
Significant reductions were found in the
incidence of in-hospital reinfarction in both
trials, of recurrent ischemia in GUSTO V and
of refractory ischemia in ASSENT 3.
Lesson #11
Benefit was shown in most of the
prespecified MI complications
Although subgroup analysis could carry
large biases, benefit was clear for many 
common MI complications in both trials.
This fact could have major positive
implications in terms of AMI morbidity.
Lesson #12
Enoxaparin can replace UFHeparin as
adjunctive therapy for fibrinolysis
Results of the enoxaparin arm of the
ASSENT 3 trial showed that this LMWH is at 
least as efficacious and safe as UFH, and
probably better.
These results were found in both the ef-
ficacy and efficacy+safety endpoints 
Despite the good design and power of these
two large randomized trials, there remain
several unanswered questions:
Regarding the association of LMWH and
fibrinolytics:
Are the results found with enoxaparin due to
a class effect of LMWHs?
Is enoxaparin a desirable anticoagulant in
conjunction with less fibrin-specific agents?
Answers to this question will be given by the
ongoing EXTRACT-TIMI 25 trial, in which
enoxaparin and UFH are being compared in a
double-blind manner in the context of
fibrinolysis for AMI.
Regarding the combination of IIb/IIIa
inhibitors and fibrinolytics:
Can these data be extrapolated to other
combinations of drugs?
What role will various pharmacologic
combinations ultimately have in conjunction
with early PCI?
Is this therapy cost-effective?
In summary:
PCI is the treatment of choice for STEMI.
However, many hospitals are unable to provide
this strategy on a 24 hours per day/7 days per
week basis. In a situation where PCI is unavail-
able, other considerations may take
precedence. First, in patients identified by
EMS as having a STEMI, prehospital lytics
may be considered, as this significantly
decreases the time to therapy. Another option
is directly transporting patients to a facility
where PCI is available. In patients less than
75 years of age who are identified as having
STEMI in a hospital that is unable to perform
early PCI, lytic or combination therapy may be
considered. In those older than 75 and unable
to receive early PCI, fibrinolytic therapy is
indicated. Finally, facilitated PCI may be
considered, in those centers where PCI is
readily available, after discussion with the
local interventional cardiology team.
This guideline addresses procedural and
practical issues raised in the ED and
prehospital setting, as the standard of care for
high-risk AMI moves toward combination
therapy using IIb/IIIa inhibitors plus
fibrinolytics and/or LMWH.
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